ANVS Berita Valas

Annovis Bio Says Phase III Study Data Release For Buntanetap In Parkinson's Disease Postponed

Drug platform company Annovis Bio, Inc. (ANVS) announced Wednesday a postponement in the Phase III study data release for buntanetap in Parkinson's Disease. This adjustment is due to ongoing data cleaning efforts to ensure the accuracy and reliability of the study results.

RTTNews | 571 days ago

Annovis Bio Says FDA Authorizes Phase 2/3 Trial For Buntanetap In Alzheimer's Disease

Annovis Bio, Inc. (ANVS), a late-stage clinical drug platform company, announced Thursday that the U.S. Food and Drug Administration (FDA) has authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer's Disease (AD).

RTTNews | 1046 days ago

Terms | Privacy | Site Map | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.17107	GBPUSD	1.3549	AUDUSD	0.65062
USDJPY	147.152	USDCAD	1.38095	USDCHF	0.80572